Clinical Trial Update: Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for KTE-X19 in minimal residual disease–positive B-cell acute lymphoblastic leukemia, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• KTE-X19 (brexucabtagene autoleucel)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: B-Cell Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Status: RECRUITING